Diabetes Drugs and Devices Market by The Drug Type (Insulin Derivatives – Short-Acting, Intermediate-Acting, Long-Acting,  Premixed, and Rapid-Acting Insulin; oral Anti-Diabetes Drugs – Alpha-Glucosidase Inhibitors, Biguanides, DPP-4 Inhibitors, Meglitinides, SGLT-2 Inhibitors, Sulphonylureas, Thiazolidinediones; and Non-Insulin Injectable Anti-Diabetes Drugs – GLP-1 Analogs), Device Type (Diabetes Monitoring and Diagnostic Devices – Analog Glucose Meter, Continuous Glucose Monitoring Devices, Glucose Test Strips, Lancets and Lancing Devices; Insulin Delivery Devices – Insulin Injectors, Pens, Pumps, Syringes) and Forecast 2017-2021

Diabetes Drugs and Devices Market by The Drug Type (Insulin Derivatives – Short-Acting, Intermediate-Acting, Long-Acting,  Premixed, and Rapid-Acting Insulin; oral Anti-Diabetes Drugs – Alpha-Glucosidase Inhibitors, Biguanides, DPP-4 Inhibitors, Meglitinides, SGLT-2 Inhibitors, Sulphonylureas, Thiazolidinediones; and Non-Insulin Injectable Anti-Diabetes Drugs – GLP-1 Analogs), Device Type (Diabetes Monitoring and Diagnostic Devices – Analog Glucose Meter, Continuous Glucose Monitoring Devices, Glucose Test Strips, Lancets and Lancing Devices; Insulin Delivery Devices – Insulin Injectors, Pens, Pumps, Syringes) and Forecast 2017-2021

The type of diabetes determines either blood sugar monitoring, insulin or oral medications as a treatment. Treatment for type 1 diabetes involves insulin injections or the use of an insulin pump, frequent blood sugar checks, and carbohydrate counting. Treatment of type 2 diabetes primarily involves monitoring of your blood sugar, along with diabetes medications, insulin or both. The elevated sugar level leads to various symptoms such as increased thirst, weight loss, high appetite, frequent and sweet smelled urination. If untreated, diabetes causes various acute and chronic life-threatening complications.

The global diabetes drugs and devices market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug type (insulin derivatives – short-acting, intermediate-acting, long-acting,  premixed, and rapid-acting insulin; oral anti-diabetes drugs – alpha-glucosidase inhibitors, biguanides, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylureas, thiazolidinediones; and non-insulin injectable anti-diabetes drugs – GLP-1 analogs), device type (diabetes monitoring and diagnostic devices – analog glucose meter, continuous glucose monitoring devices, glucose test strips, lancets and lancing devices; insulin delivery devices – insulin injectors, pens, pumps, syringes, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).

The global diabetes drugs and devices market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global diabetes drugs and devices market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global diabetes drugs and devices market and included in this report are Abbott Laboratories, Inc., AstraZeneca plc, B Braun Melsungen AG, Bayer HealthCare AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, DexCom, Inc., Eli Lilly and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Medtronic, Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Sanofi, and Takeda Pharmaceutical Co. Ltd.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Diabetes Drugs and Devices Market

1. Drug Type
1.1. Insulin
1.1.1. Short-Acting Insulin Derivatives
1.1.2. Intermediate-Acting Insulin Derivatives
1.1.3. Long-Acting Insulin Derivatives
1.1.4. Premixed Insulin Derivatives
1.1.5. Rapid-Acting Insulin Derivatives
1.2. Oral Anti-Diabetes Drugs
1.2.1. Alpha-Glucosidase Inhibitors
1.2.2. Biguanides
1.2.3. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
1.2.4. Meglitinides
1.2.5. Sodium/Glucose Cotransporter 2 (SGLT-2) Inhibitors
1.2.6. Sulphonylureas
1.2.7. Thiazolidinediones
1.3. Non-Insulin Injectable Anti-Diabetes Drugs
1.3.1. Glucagon-like peptide-1 (GLP-1) Analogs

2. Device Type
2.1. Diabetes Monitoring And Diagnostic Devices
2.1.1. Analog Glucose Meter
2.1.2. Continuous Glucose Monitoring Devices
2.1.3. Glucose Test Strips
2.1.4. Lancets And Lancing Devices
2.1.5. Others
2.2. Insulin Delivery Devices
2.2.1. Insulin Injectors
2.2.2. Insulin Pens
2.2.3. Insulin Pumps
2.2.4. Insulin Syringes

3. Company Profiles
3.1. Abbott Laboratories, Inc.
3.2. AstraZeneca plc
3.3. B. Braun Melsungen AG
3.4. Bayer HealthCare AG
3.5. Becton, Dickinson & Company
3.6. Boehringer Ingelheim GmbH
3.7. DexCom, Inc.
3.8. Eli Lilly and Company
3.9. F. Hoffmann-La Roche Ltd.
3.10. GlaxoSmithKline plc
3.11. Johnson & Johnson
3.12. Lupin Limited
3.13. Medtronic, Inc.
3.14. Merck & Co., Inc.
3.15. Novartis International AG
3.16. Novo Nordisk A/S
3.17. Sanofi
3.18. Takeda Pharmaceuticals

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish